Sign in

You're signed outSign in or to get full access.

EB

Evofem Biosciences, Inc. (EVFM)·Q4 2024 Earnings Summary

Executive Summary

  • Q4 2024 revenue accelerated to $7.10M, up 47% YoY and 58% QoQ, driven by Phexxi pull-forward ahead of the Jan 1, 2025 WAC increase and initial SOLOSEC contribution; operating loss narrowed to $1.0M (vs. $3.4M LY) while sales & marketing fell to 31% of net sales, the best quarterly ratio since launch .
  • Full-year 2024 net sales rose 6% to $19.36M and loss from operations improved 57% to $(7.68)M amid a 27% reduction in total operating expense (excl. $0.6M amortization) versus 2023, evidencing cost discipline and operating leverage .
  • Post-quarter, Evofem signed a license & supply agreement expected to cut Phexxi manufacturing costs by 55–60% from current levels, a potential structural margin catalyst in 2025+ and for ex-U.S. expansion .
  • Merger timeline extended: Fifth amendment sets Aditxt funding of $1.5M by Apr 7, 2025, a special meeting by Sep 26, 2025, and targeted close by Sep 30, 2025—pushing out the closing window from late 2024 and highlighting funding/approval execution risks .

What Went Well and What Went Wrong

  • What Went Well

    • Strong Q4 top-line and improved operating metrics: net sales $7.10M (+47% YoY; +58% QoQ), operating loss $(1.0)M (vs. $(3.4)M LY), and S&M at 31% of sales, the most favorable quarterly ratio since Phexxi launch .
    • Annual operating improvement: FY24 loss from operations improved 57% to $(7.68)M as total operating expense fell 27% YoY (excl. amortization), with S&M as % of sales dropping to 47% vs. 64% in 2023 .
    • Strategic cost leverage/catalysts: Windtree agreement expected to reduce Phexxi COGS by 55–60%, improving margins and enabling entry into price-sensitive international markets .

  • What Went Wrong

    • Net loss in Q4 widened sequentially to $(3.04)M (vs. $(2.37)M in Q3), including a $0.7M non-cash impairment and higher amortization tied to SOLOSEC; restricted cash remained only ~$0.7M at year-end, underscoring liquidity tightness .
    • Revenue mix/visibility: While management said the “vast majority” of 2024 net sales came from Phexxi, the company did not disclose product-level revenue; SOLOSEC relaunch began only in November, leaving limited visibility into its pace of uptake .
    • M&A timing pushed out: Merger closing goal slipped from “late 2024” to by Sep 30, 2025, contingent on funding and shareholder approvals, adding timeline risk and potential overhang .

Financial Results

Quarterly P&L snapshot

MetricQ4 2023Q2 2024Q3 2024Q4 2024
Net Product Sales ($M)$4.84 $4.16 $4.50 $7.10
Cost of Goods Sold ($M)$0.95 $0.77 $0.87 $1.51
Amortization of Intangible ($M)$0.00 $0.00 $0.30 $0.32
R&D ($M)$1.38 $0.27 $0.33 $0.65
Selling & Marketing ($M)$2.63 $2.24 $2.38 $2.21
G&A ($M)$3.25 $2.27 $3.05 $3.42
Total Operating Expenses ($M)$8.22 $5.55 $6.94 $8.11
Loss from Operations ($M)$(3.38) $(1.39) $(2.44) $(1.00)
Net Income (Loss) ($M)$(2.11) $1.35 $(2.37) $(3.04)
Basic EPS ($)$(0.44) $0.02 $(0.02) $(0.03)

Annual metrics

MetricFY 2023FY 2024
Net Product Sales ($M)$18.22 $19.36
Total Operating Expenses ($M)$36.07 $27.04
Loss from Operations ($M)$(17.85) $(7.68)
Net Income (Loss) ($M)$52.98 $(8.86)
S&M as % of Net Sales64% 47%

Notes

  • Q4 sales strength reflected Phexxi pull-forward ahead of WAC change and initial SOLOSEC revenue post November relaunch .
  • Q4 net loss included a $0.7M non-cash impairment on construction-in-process equipment .
  • Year-over-year 2023 net income was driven by a large, non-recurring gain on debt extinguishment, distorting comparisons .

KPI highlights

KPIQ4 2024FY 2024
Sales & Marketing as % of Net Sales31% (best since launch) 47% (vs. 64% in 2023)

Segment/Product breakdown

  • Company disclosed that the vast majority of 2024 net sales were from Phexxi; SOLOSEC net sales also contributed post-acquisition/relaunch. No product-level revenue detail provided .

Liquidity

  • Restricted cash at 12/31/24: $0.74M (vs. $0.58M at 12/31/23) .
  • October 2024: $2.7M raised via Series F-1 preferred from Aditxt; used in part to pay FDA obligations .

Guidance Changes

MetricPeriodPrevious GuidanceCurrent GuidanceChange
Phexxi COGS (manufacturing cost)2025+N/AExpect 55–60% reduction from current levels after Windtree manufacturing transition Lowered (cost)
Merger with Aditxt – closing timeframeTransaction timelineTarget “late 2024” close Fifth amendment: fund $1.5M by Apr 7, 2025; special meeting by Sep 26, 2025; consummate by Sep 30, 2025 Extended timeline
Revenue/EPS2025None disclosedNone disclosedMaintained (no guidance)

Earnings Call Themes & Trends

Note: A Q4 2024 earnings call transcript was not available; themes below reflect disclosures from Q2, Q3, and Q4 primary documents.

TopicPrevious Mentions (Q-2 and Q-1)Current Period (Q4 2024)Trend
Product portfolio expansion (SOLOSEC)Acquired global rights; plan to relaunch; highlighted clinical positioning (single-dose for BV and trichomoniasis) Relaunched SOLOSEC in Nov 2024; contributed to Q4 sales Improving (commercialization)
International expansion (Phexxi)Licensed Middle East rights; UAE submission targeted by YE 2024 Strategy to lower COGS expected to enable entry into price-sensitive global markets Advancing (cost-enabled)
Sales & marketing efficiencyEmphasized OpEx cuts; Q2/Q3 operating loss improvements Q4 S&M 31% of sales (best quarterly ratio); FY S&M 47% of sales Improving (leverage)
Manufacturing/COGS—Windtree agreement expected to reduce Phexxi COGS by 55–60% Positive structural catalyst
M&A/Capital structureAditxt investments and merger agreement; targeted late-2024 close Fifth amendment extends close to Sep 30, 2025, with interim funding and meeting milestones Extended timeline; execution risk
Reimbursement/AccessMedi‑Cal rebate reduced 7.4%; Hello Alpha telemedicine partnership —Foundation in place

Management Commentary

  • “Our revenue growth and improved loss from operations in 2024 testify to the strength and persistence of this company... In 2025, our strategy is to drive domestic sales growth with our innovative products – PHEXXI and SOLOSEC. Having two revenue generating FDA‑approved products mitigates market risk for investors...” — Saundra Pelletier, CEO .
  • “The meaningful decrease in the per-box cost of PHEXXI that we expect to achieve with Windtree’s assistance should allow Evofem to take PHEXXI into new, price-sensitive global markets...” — Saundra Pelletier, CEO .
  • “We continue to advance Evofem’s strategy to grow revenues organically and through strategic acquisitions and alliances... We acquired and recently relaunched SOLOSEC... We also forged an agreement that paves the way for the commercialization of Phexxi in the GCC...” — Saundra Pelletier, CEO (Q3) .

Q&A Highlights

  • No Q4 2024 earnings call transcript was available; therefore, no Q&A disclosures to report [ListDocuments returned no Q4/Q1 2025 transcript; see absence in results].

Estimates Context

  • Wall Street consensus (S&P Global) for Q4 2024 and prior quarters could not be retrieved at this time due to API rate limits; as a result, beat/miss versus consensus is unavailable here [GetEstimates error: “Daily Request Limit... Exceeded”].
  • Given limited micro-cap coverage and lack of published guidance, investors should focus on sequential/YoY trends, operating leverage, and structural margin catalysts evidenced in company filings .

Key Takeaways for Investors

  • Q4 inflection: strong sequential and YoY revenue growth with materially better operating loss and S&M efficiency signals tangible operating leverage heading into 2025 .
  • Margin catalyst: expected 55–60% Phexxi COGS reduction is a meaningful structural tailwind to gross margin and international scalability if executed on timeline .
  • Second revenue pillar: SOLOSEC relaunch adds diversification; near‑term focus is monitoring prescription uptake and contribution margin progression .
  • Liquidity tight: restricted cash ~$0.74M at year‑end; continued dependence on external funding/merger progress elevates financing risk .
  • Merger overhang extended: Aditxt closing shifted to by Sep 30, 2025 with interim milestones—watch funding and shareholder approvals as binary catalysts .
  • Estimate uncertainty: With consensus unavailable, trading setup likely centers on execution of cost transition, SOLOSEC ramp, and evidence of sustained S&M leverage. Near-term catalysts include manufacturing transfer milestones and any geographic expansion updates .

Sources

  • Q4/FY 2024 results press release and financial tables .
  • Form 8‑K including Item 2.02 and Exhibit 99.1 (Q4/FY 2024) .
  • Cost reduction press release (Windtree agreement) .
  • Q3 2024 results release and 8‑K .
  • Q2 2024 results release and 8‑K .